Alogliptin Impurity 1430222-09-5
Product Overview
Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes. Its impurity reference standards are critical for drug R&D, quality control, and impurity profiling. We offer high-purity Alogliptin impurity reference standards, including popular impurities like Impurity Q (CAS: 3891-07-4), Impurity 5 (CAS: 850649-62-6), and Impurity 19 (CAS: 55-21-0).
Key Features
High Purity: HPLC purity ≥95%, with select batches reaching 99%+. COA reports, HNMR, MS, and HPLC spectra provided.
Comprehensive Structural Verification: IR, UV, and 2D NMR (COSY, NOESY, HMBC, HMQC) data for unambiguous impurity identification.
In-Stock Availability: Multiple packaging options (10mg–100g) with expedited shipping for urgent requests.
Regulatory Support: Impurity source analysis, QC strategy development, and analytical method optimization services.
Applications
Drug Discovery: Impurity structural elucidation, metabolite profiling, and degradation pathway studies.
Quality Control: Impurity limit determination, stability testing, and lot-to-lot consistency evaluation.
Bioequivalence: Impurity spectrum comparison for generic drug development.
Technical Expertise
Over a decade of experience in impurity R&D, with custom synthesis capabilities.
Advanced SFC purification technology for complex impurity isolation.
End-to-end solutions including process scale-up and CMC optimization.
China
